MacroGenics, Inc. Loss Form

Company: MacroGenics, Inc.

Ticker: (NASDAQGS) MGNX

Deadline

Passed

Lead Plaintiff Deadline: November 12, 2019

Never Miss Another Deadline

Choose your preferred way to stay informed of new case launches and settlement deadlines.

Scan the QR code or click the button to join.

Join on WhatsApp

Get Updates by Email

Subscribe for email notifications.

Full Name

No spam, opt-out anytime, alert list is free.

Allegations

(a) the Company had conducted the progression-free survival (“PFS”) and first interim overall survival (“OS”) analyses for the SOPHIA trial by no later than October 10, 2018; (b) the October 2018 PFS analysis showed a 0.9 month improvement in PFS; and (c) the October 2018 OS interim analysis did not produce a statistically significant result and the interim OS Kaplan-Meier curves crossed in several spots (thereby violating the constant hazard assumption) and separated late.